STOCK TITAN
  1. Home
  2. Sec-filings
  3. KURA
  4. [Form 4] Kura Oncology, Inc. Insider Trading Activity

Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026 at a weighted average price of $9.8233 per share. The trades were executed in multiple lots at prices ranging from $9.56 to $9.98.

The shares sold had been acquired upon vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following this transaction, Leoni directly holds 182,345 Kura Oncology shares.

Positive

  • None.

Negative

  • None.
Insider Leoni Mollie
Role Chief Medical Officer
Sold 84,929 shs ($834K)
Type Security Shares Price Value
Sale Common Stock 84,929 $9.8233 $834K
Holdings After Transaction: Common Stock — 182,345 shares (Direct, null)
Footnotes (1)
  1. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 84,929 shares Common stock sold on June 18, 2026
Weighted average sale price $9.8233 per share Open-market sale on June 18, 2026
Post-transaction holdings 182,345 shares Direct ownership after June 18, 2026 sale
Trade price range $9.56–$9.98 per share Multiple trades comprising reported sale
10b5-1 plan adoption date March 19, 2026 Rule 10b5-1 trading plan for the sale
Award vesting period Jan 26, 2022–Jan 26, 2026 Period when RSUs and PRSUs vested
Rule 10b5-1 trading plan regulatory
"The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"The shares sold were acquired ... upon vesting of restricted stock units and performance restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
performance restricted stock units financial
"upon vesting of restricted stock units and performance restricted stock units during the period"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leoni Mollie
(Last)(First)(Middle)
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026S(1)84,929D$9.8233(2)182,345D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units and performance restricted stock units during the period from January 26, 2022 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
2. This transaction was executed in multiple trades at prices ranging from $9.56 to $9.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Teresa Bair, Attorney-in-fact for Mollie Leoni06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kura Oncology (KURA) report for Mollie Leoni?

Kura Oncology reported that Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026, at a weighted average price of $9.8233 per share, and now directly holds 182,345 shares afterward.

At what price did Kura Oncology (KURA) CMO sell her shares?

Mollie Leoni’s sale used a weighted average price of $9.8233 per share, with individual trades executed between $9.56 and $9.98. This range reflects multiple trade executions aggregated into a single reported transaction in the filing.

How many Kura Oncology (KURA) shares does Mollie Leoni hold after the sale?

After selling 84,929 shares, Chief Medical Officer Mollie Leoni directly holds 182,345 Kura Oncology common shares. This post-transaction holding figure comes directly from the Form 4 and represents her remaining reported ownership position.

Were the Kura Oncology (KURA) insider sales under a Rule 10b5-1 plan?

Yes. The Form 4 states that Mollie Leoni’s sales were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than decided spontaneously.

How did Mollie Leoni originally acquire the Kura Oncology (KURA) shares sold?

The filing explains that the sold shares were acquired through vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. These equity awards are part of compensation rather than open-market purchases.